Home Tags MilliporeSigma

Tag: MilliporeSigma

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

MilliporeSigma and Angiex Collaborate to Speed-up Clinical Readiness for the Development...

MilliporeSigma, the US-based life science business of Merck KGaA, Darmstadt, Germany, has agreed to support Cambridge, Massachusetts-based Angiex ability to speed-up the development of...

Trial of High Efficiency TFF Capsule Prototype for ADC Purification

Antibody-drug conjugates (ADCs) are an emerging class of highly targeted cancer therapies in which a monoclonal antibody is chemically conjugated to a cytotoxic drug...

MilliporeSigma Introduces Integrated ADC Services to Reduce Complexity and Accelerate Time...

During the 7th World ADC Summit in Berlin, Germany, held February 20 - 22, 2017, MilliporeSigma announced that the company will now offer complete...